Reblozyl — Total Revenues
Bristol-Myers Squibb Reblozyl — Total Revenues decreased by 16.7% to $555M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.1%, from $478M to $555M. Over 4 years (FY 2021 to FY 2025), Reblozyl — Total Revenues shows an upward trend with a 43.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration, successful clinical adoption, or expanded patient access, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Reblozyl, a therapeutic produc...
Peer comparison
Comparable to revenue metrics for specialized biologic or oncology products at other large-cap pharmaceutical companies, often evaluated against consensus growth estimates for high-value therapeutic assets.
bmy_segment_reblozyl_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $128M | $160M | $151M | $156M | $172M | $190M | $199M | $206M | $234M | $248M | $320M | $354M | $425M | $447M | $547M | $478M | $568M | $615M | $666M | $555M |
| QoQ Change | — | +25.0% | -5.6% | +3.3% | +10.3% | +10.5% | +4.7% | +3.5% | +13.6% | +6.0% | +29.0% | +10.6% | +20.1% | +5.2% | +22.4% | -12.6% | +18.8% | +8.3% | +8.3% | -16.7% |
| YoY Change | — | — | — | — | +34.4% | +18.8% | +31.8% | +32.1% | +36.0% | +30.5% | +60.8% | +71.8% | +81.6% | +80.2% | +70.9% | +35.0% | +33.6% | +37.6% | +21.8% | +16.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's reblozyl — total revenues?
- Bristol-Myers Squibb (BMY) reported reblozyl — total revenues of $555M in Q1 2026.
- How has Bristol-Myers Squibb's reblozyl — total revenues changed year-over-year?
- Bristol-Myers Squibb's reblozyl — total revenues increased by 16.1% year-over-year, from $478M to $555M.
- What is the long-term trend for Bristol-Myers Squibb's reblozyl — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's reblozyl — total revenues has grown at a 43.4% compound annual growth rate (CAGR), from $551M to $2.33B.
- What does reblozyl — total revenues mean?
- The total revenue generated from sales of the drug Reblozyl.